DermTech, Inc. announced an agreement with a Blues plan in Hawaii. The contract, which is in addition to a favorable coverage policy, enhances access to the foundational assay of the DermTech Melanoma Test (DMT) for the nearly 800,000 members of this plan. The DMT is an innovative, non-invasive way to enhance melanoma detection with a greater than 99% negative predictive value (NPV).